NewLink Genetics Corporation (NLNK) Quote

I see form t buying and selling on the open and close.

no qtly report yet? anybody?

$NLNK back to $.50

if newlink was attempting a vacine for the carona virus we would have already heard something. put down the crackpipe and step away from the keyboard.

what announcement?

another question, was I looking at it right? this ticker has a float of only 37 million? that should float on air if good news was published, hoping for the end of the month for the announcement

the stock price is much closer to the offering price by evercel, another offer would be a nice profit opportunity.

I saw some form t purchases yesterday while watching the trades, and it spiked a bit after that, but have yet to see anything on sedar, or news.

I heard NLNK had something for this, and had plans to check to see what this site was saying NLNK submitting to the FDA "by the end of the month?" actually that's what just brought me to this site. spot on looks good, very good!!

$NLNK 38 infected coronavirus patients CURED in China https://rt.com/news/479148-coronavirus-patients-cured-china/

* * $NLNK Video Chart 12-26-2019 * *

Link to Video - click here to watch the technical chart video

selling bottoms since 2009.
seriously though, trying to protect gains.. only took a quarter off but want to ride this one. volume is through the roof

Help: What happened in mid 2018, to make so many institutions sell?

Near target $9 conservatively. More investors will pile in after Christmas

* * $NLNK Video Chart 12-24-2019 * *

Link to Video - click here to watch the technical chart video

Buy!

Clay your posts are like seeing roadkill on the side of the road. When you are an old man you will look back and see how you wasted your life away you spam artist.

Click the link on last post then it seems to need a browser refresh to actually work.

Sorry not sure why this is.

Cheers

January/February/March are by far and away the greatest 3 months in historical stock price returns for NLNK.

https://stockcharts.com/freecharts/seasonality.php?symbol=NLNK


Buckle up January Effect should be the Full Monty!

This is January Effect Play! The reasoning was tax loss selling it gave back so much. This time of year even with truly positive fundamental news (which did occur) a stock can still weaken. Look at this out a month or more. Only Day traders got F'd.

* * $NLNK Video Chart 12-20-2019 * *

Link to Video - click here to watch the technical chart video

News: $NLNK NewLink Genetics Announces FDA Approval of Ebola Vaccine V920 (ERVEBO®)

AMES, Iowa, Dec. 20, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) announced today that, after priority review, the FDA has granted approval of ERVEBO® , or Zaire Ebola virus vaccine V920 (rVSV∆G-ZEBOV-GP), as confirmed by our partner, Merck (NYS...

Read the whole news NLNK - NewLink Genetics Announces FDA Approval of Ebola Vaccine V920 (ERVEBO®)

Claytrader predicts horizontal lines.

* * $NLNK Video Chart 10-01-2019 * *

Link to Video - click here to watch the technical chart video

* * $NLNK Video Chart 09-18-2019 * *

Link to Video - click here to watch the technical chart video

News: $NLNK NewLink Genetics Presents Updated NLG802 Results at the Immuno-Oncology 2019 World Congress

NLG802, a prodrug of indoximod, produced significantly higher pharmacokinetic (PK) exposure in patients compared to molar equivalent of indoximod while maintaining encouraging safety profile Notable response in 5 th line pancreatic cancer patient re-challenged with chemotherapy after ...

Find out more https://marketwirenews.com/news-releases/newlink-genetics-presents-updated-nlg802-results-at-the-immuno-oncology-2019-world-congress-8234968.html

* * $NLNK Video Chart 03-19-2019 * *

Link to Video - click here to watch the technical chart video

What a shock...after "Clay", no new posts.

* * $NLNK Video Chart 11-15-18 * *

Link to Video - click here to watch the technical chart video

Agreed. They said they would need $10 mil per quarter to operate. $40 mil per year. They have $137 mil. That’s where they’re getting 2H 2021 and that is assuming no new revenues.

I think they’ve just guaranteed their existence through further than 2H 2021 especially if they increase their revenue stream.

I’m hoping they’re doing it because they see the potential in indoximod.

They see the value in cash for sure and I think they would be looking for work elsewhere if they had no belief in the value of their technology.

Early R&D without revenues is a blackhole for cash. The move hopefully extends the available cash deep into 2021 before more is needed.

Best, Terry

I’m hoping they’re doing it because they see the potential in indoximod. Hunkering down and pushing through. From what I’ve read so far, the results seem positive.

NLNK retrenchment:

https://globenewswire.com/news-release/2018/07/31/1544941/0/en/NewLink-Genetics-Announces-Clinical-Plan-Reports-Second-Quarter-2018-Financial-Results-and-Revises-Cash-Guidance.html

I have no opinion on whether the announced retrenchment was wise or not but it looks good from a distance in today's continuing flight to overpriced blue chips.

Best, Terry

NewLink Genetics Announces Positive Updated Phase 1 Data with Indoximod Plus Radio-Immunotherapy for Pediatric Patients with DIPG Presented at ISPNO 2018

AMES, Iowa--(BUSINESS WIRE)--NewLink Genetics Corporation (NASDAQ:NLNK), reported that updated Phase 1 data evaluating indoximod plus front-line radiation and maintenance chemotherapy for the treatment of pediatric patients with newly diagnosed diffuse intrinsic pontine glioma (DIPG) were presented Sunday, July 1, at the International Symposium of Pediatric Neuro-Oncology (ISPNO) 2018 Annual Meeting in Denver.

Data were presented on ten newly diagnosed DIPG patients, all of whom had initiated therapy at the time of this assessment. All (10/10) demonstrated initial symptomatic improvement. Eight of ten had completed radiation, with the remaining 2 of 10 patients continuing radiotherapy. While a subset of the patient cohort developed inflammatory and other adverse symptomology, a common occurrence in this patient population, these symptoms were actively managed. Currently, 9/10 patients remain on study, with the longest time on study of 8.5 months. These data include more mature follow-up on the 6 patients previously presented at AACR 2018.

“These data continue to demonstrate the potential for indoximod plus radiochemotherapy as a combination treatment regimen which may improve disease related symptoms for these pediatric patients with an otherwise dire prognosis,” said Dr. Theodore S. Johnson, M.D., Ph.D., Associate Professor of Pediatrics at Augusta University, lead investigator for the trial. “We remain encouraged and look forward to additional data as the study proceeds.”

This DIPG cohort is a subset of NLG2105, a Phase 1 study evaluating indoximod, NewLink’s IDO pathway inhibitor, in combination with radiation and chemotherapy for pediatric patients with malignant brain tumors. The DIPG cohort has been expanded from an initial pilot study based on early safety and efficacy data and is currently enrolling with a target of 30 DIPG patients.

About Diffuse Intrinsic Pontine Glioma (DIPG)

Diffuse intrinsic pontine glioma, or DIPG, is a rare, aggressive brain tumor found in the brain stem that almost exclusively affects children...

https://tinyurl.com/y9b87rd8

Just another "lost" biotech with promise as the smart money that fled to the dumbos is receiving their "reward."

Best, Terry

http://www.stockscores.com/charts/charts/?ticker=NLNK

* * $NLNK Video Chart 04-06-18 * *

Link to Video - click here to watch the technical chart video

NewLink Genetics Announces Review of Clinical Programs

Source: GlobeNewswire Inc.

NewLink Genetics Corporation (NASDAQ:NLNK) today announced a review of its clinical programs.
This morning’s announcement by Incyte and Merck on the ECHO-301 trial for patients with advanced melanoma is a disappointing result for the IDO field. Indoximod, NewLink Genetics’ IDO pathway inhibitor, has a differentiated mechanism of action (MOA) which may demonstrate clinical benefit for patients where direct enzymatic inhibitors have not. In light of Incyte’s announcement, however, NewLink is undertaking a review of its clinical programs and will provide an update when it is completed.

NewLink Genetics has generated data for indoximod across several indications, and in combination with different modalities, suggesting the potential for indoximod to improve the outcomes for patients with cancer. The Company will present additional data at AACR next week, including a poster presentation further supporting indoximod’s differentiated MOA and a plenary session presenting encouraging early clinical data of indoximod plus radiation for pediatric patients with diffuse intrinsic pontine glioma (DIPG), a rare and lethal form of brain cancer.

About Indoximod

Indoximod is an investigational, orally available small molecule targeting the IDO pathway. The IDO pathway is a key immuno-oncology target involved in regulating the tumor microenvironment and immune escape. Indoximod is being evaluated in combination with treatment regimens including anti-PD-1/PD-L1 agents, cancer vaccines, radiation, and chemotherapy across multiple indications such as melanoma, pancreatic cancer and other malignancies.

About NewLink Genetics Corporation

NewLink Genetics is a late-stage biopharmaceutical company focusing on discovering, developing and commercializing novel immuno-oncology product candidates to improve the lives of patients with cancer. NewLink Genetics' IDO pathway inhibitors are designed to harness multiple components of the immune system to combat cancer. For more information, please visit www.newlinkgenetics.com and follow us on Twitter @NLNKGenetics.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements of NewLink Genetics that involve substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements, within the meaning of The Private Securities Litigation Reform Act of 1995. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "target," "potential," "will," "could," "should," "seek" or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among others, statements about results of its clinical trials for product candidates; its timing of release of data from ongoing clinical studies; its plans related to moving additional indications into clinical development; and any other statements other than statements of historical fact. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that NewLink makes due to a number of important factors, including those risks discussed in "Risk Factors" and elsewhere in NewLink Genetics' Annual Report on Form 10-K for the year ended December 31, 2017 and other reports filed with the U.S. Securities and Exchange Commission (SEC). The forward-looking statements in this press release represent NewLink Genetics’ views as of the date of this press release. NewLink Genetics anticipates that subsequent events and developments will cause its views to change. However, while it may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. You should, therefore, not rely on these forward-looking statements as representing NewLink Genetics' views as of any date subsequent to the date of this press release.

Investor Contact:

Lisa Miller
Director of Investor Relations
NewLink Genetics
515-598-2555
lmiller@linkp.com

Media Contact:

Sharon Correia
VP, Integrated Communications
LaVoieHealthScience
617-374-8800, ext. 105
scorreia@lavoiehealthscience.com



Primary Logo

scared people shouldn't invest all this selling has nothing to do with NLNK

Bounce coming it look like

Right behind you

panic selling off the incyte merck results., im buying

http://www.barchart.com/detailedquote/stocks/NLNK

I’m loading up at these levels

http://www.barchart.com/opinions/stocks/NLNK

Newlink Genetics Cor (NLNK)
8.76 ? 0.2 (2.34%)
Volume: 707,605 @ 4:36:46 PM EST ET
Bid Ask Day's Range
7.95 9.75 8.56 - 8.93
NLNK Detailed Quote

Kelly does your DD still stand on its own here?

I am thinking to drop some money here.

http://www.barchart.com/opinions/stocks/NLNK

https://www.stockscores.com/charts/charts/?ticker=NLNK

You're right, I have done very well in the past on AZN and w/ NLNK I love the float size and the chart is a thing of beauty w/ no gaps below left to fill.

Sweet, I think azn is a great company too and them being involved gives me a lot of confidence in this investment